Literature DB >> 12414973

Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Heather J Ezelle1, Dubravka Markovic, Glen N Barber.   

Abstract

Hepatitis C virus (HCV), a major etiologic agent of hepatocellular carcinoma, presently infects approximately 400 million people worldwide, making the development of protective measures against HCV infection a key objective. Here we have generated a recombinant vesicular stomatitis virus (VSV), which expresses the HCV structural proteins, by inserting the contiguous Core, E1, and E2 coding region of HCV into the VSV genome. Recombinant VSV expressing HCV Core, E1, and E2 (VSV-HCV-C/E1/E2) grew to high titers in vitro and efficiently expressed the incorporated HCV gene product, which became fully processed into the individual HCV structural proteins. Biochemical and biophysical analysis indicated that the HCV Core, E1, and E2 proteins assembled to form HCV-like particles (HCV-LPs) possessing properties similar to the ultrastructural properties of HCV virions. Mice immunized with VSV-HCV-C/E1/E2 generated cell-mediated immune responses to all of the HCV structural proteins, and humoral responses, particularly to E2, were also readily evident. Our data collectively indicate that engineered VSVs expressing HCV Core, E1, and E2 and/or HCV-LPs represent useful tools in vaccine and immunotherapeutic strategies designed to address HCV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414973      PMCID: PMC136870          DOI: 10.1128/jvi.76.23.12325-12334.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.

Authors:  C Y Kang; L Luo; M A Wainberg; Y Li
Journal:  Biol Chem       Date:  1999-03       Impact factor: 3.915

2.  Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope.

Authors:  K Haglund; J Forman; H G Kräusslich; J K Rose
Journal:  Virology       Date:  2000-03-01       Impact factor: 3.616

3.  Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway.

Authors:  S Balachandran; P C Roberts; T Kipperman; K N Bhalla; R W Compans; D R Archer; G N Barber
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

4.  Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model.

Authors:  T Arichi; T Saito; M E Major; I M Belyakov; M Shirai; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

5.  A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-alpha promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL).

Authors:  Y Nishimura; A Kamei; S Uno-Furuta; S Tamaki; G Kim; Y Adachi; K Kuribayashi; Y Matsuura; T Miyamura; Y Yasutomi
Journal:  Vaccine       Date:  1999-11-12       Impact factor: 3.641

6.  Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

Authors:  X Paliard; Y Liu; R Wagner; H Wolf; J Baenziger; C M Walker
Journal:  AIDS Res Hum Retroviruses       Date:  2000-02-10       Impact factor: 2.205

7.  Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations.

Authors:  E J Gordon; R Bhat; Q Liu; Y F Wang; C Tackney; A M Prince
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice.

Authors:  X S Liu; I Abdul-Jabbar; Y M Qi; I H Frazer; J Zhou
Journal:  Virology       Date:  1998-12-05       Impact factor: 3.616

9.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Effect of retreatment with interferon alone or interferon plus ribavirin on hepatitis C virus quasispecies diversification in nonresponder patients with chronic hepatitis C.

Authors:  M Gerotto; D G Sullivan; S J Polyak; L Chemello; L Cavalletto; P Pontisso; A Alberti; D R Gretch
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

View more
  21 in total

1.  Endogenous virus and hepatitis C virus-like particle budding in BHK-21 cells.

Authors:  Emmanuelle Blanchard; Denys Brand; Philippe Roingeard
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Membrane binding properties and terminal residues of the mature hepatitis C virus capsid protein in insect cells.

Authors:  Tomoaki Ogino; Hiroyuki Fukuda; Shinobu Imajoh-Ohmi; Michinori Kohara; Akio Nomoto
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

Review 4.  Molecular biology of hepatitis C virus.

Authors:  Tetsuro Suzuki; Hideki Aizaki; Kyoko Murakami; Ikuo Shoji; Takaji Wakita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

5.  Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.

Authors:  Ayaz M Majid; Heather Ezelle; Sangeeta Shah; Glen N Barber
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.

Authors:  Yuanmei Ma; Jianrong Li
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

8.  Involvement of a bovine viral diarrhea virus NS5B locus in virion assembly.

Authors:  Israrul H Ansari; Li-Mei Chen; Delin Liang; Laura H Gil; Weidong Zhong; Ruben O Donis
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Characterization of hepatitis C virus core protein multimerization and membrane envelopment: revelation of a cascade of core-membrane interactions.

Authors:  Li-Shuang Ai; Yu-Wen Lee; Steve S-L Chen
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

10.  Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection.

Authors:  Hideki Aizaki; Kenichi Morikawa; Masayoshi Fukasawa; Hiromichi Hara; Yasushi Inoue; Hideki Tani; Kyoko Saito; Masahiro Nishijima; Kentaro Hanada; Yoshiharu Matsuura; Michael M C Lai; Tatsuo Miyamura; Takaji Wakita; Tetsuro Suzuki
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.